Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study. The ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Beam Therapeutics (NASDAQ:BEAM) fell sharply in the morning hours Tuesday after multiple media reports indicated that a patient has died following the administration of the company's experimental gene ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

Q3 2024 Earnings Call Transcript November 4, 2024 Vertex Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.38, expectations were $4.14. Operator: Good day. And welcome to ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...

The night before Calvin Dickey Jr.'s first and final football practice at Bucknell University, he slept in his parents' hotel room.